Your shopping cart is currently empty
Bioactive Compound Database
Faced with the escalating costs and stringent safety requirements of traditional de novo drug discovery, the industry is increasingly shifting toward high-efficiency alternative strategies. Rather than starting from scratch, leveraging molecules with established biological activity significantly enhances the probability of identifying high-potential hits, as these compounds possess far greater drug-like potential than general screening libraries. This logic extends to the strategic practice of drug repurposing, which targets
FDA-approved or clinical-stage drugs for new therapeutic indications. By utilizing existing clinical data on human tolerance, pharmacokinetics, and safety profiles, researchers can drastically compress development timelines and minimize financial risk. Powered by modern big data analytics and advanced computational modeling, this activity-based discovery model offers a more robust and cost-effective pathway for pharmaceutical innovation.































